FineMark National Bank & Trust’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

FineMark National Bank & Trust’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-250	Closed	-$6K	–	1128
2016 Q4	$6K	Sell	250 -300	-55%	-$5.86K	﹤0.01%	1046
2016 Q3	$12K	Buy	550 +250	+83%	+$5.87K	﹤0.01%	916
2016 Q2	$7K	Hold	300	–	–	﹤0.01%	1026
2016 Q1	$6K	Hold	300	–	–	﹤0.01%	1021
2015 Q4	$15K	Buy	300 +150	+100%	+$7.27K	﹤0.01%	874
2015 Q3	$6K	Hold	150	–	–	﹤0.01%	1074
2015 Q2	$7K	Buy	+150	New	+$6.04K	﹤0.01%	1076

Other funds holding PTLA

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

FineMark National Bank & Trust's PTLA Position: Q1 2017 in Review

FineMark National Bank & Trust sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q1 2017, closing a stake of 250 shares — an estimated $6K sold.

FineMark National Bank & Trust first reported a position in PTLA in Q2 2015 and held it in 7 quarters. The position peaked at $15K in Q4 2015. 180 funds tracked by Wall St. Rank hold PTLA as of Q1 2017.

FineMark National Bank & Trust reported no remaining Portola Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
FineMark National Bank & Trust sold 250 Portola Pharmaceuticals, Inc. shares in Q1 2017, an estimated $6K.
FineMark National Bank & Trust first reported a position in Portola Pharmaceuticals, Inc. in Q2 2015 and held it in 7 quarters.
FineMark National Bank & Trust's Portola Pharmaceuticals, Inc. position peaked at $15K in Q4 2015.
180 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q1 2017.

Based on FineMark National Bank & Trust's 13F filing for Q1 2017, filed 12 May 2017.